<DOC>
	<DOCNO>NCT02150499</DOCNO>
	<brief_summary>This study levalbuterol tartrate HFA inhalation aerosol MDI pediatric subject birth ≤ 48 month age go Emergency Department ( ED ) physician 's office acute bronchospasm . Subjects present ED physician 's office acute bronchospasm must history reactive airway disease , base subject ' parent/guardian report .</brief_summary>
	<brief_title>A Study Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler ( MDI ) Pediatric Subjects</brief_title>
	<detailed_description>This study determine safety tolerability cumulative dosing levalbuterol tartrate HFA inhalation aerosol MDI use valved hold chamber facemask pediatric subject birth ≤ 48 month age acute bronchospasm . It randomize , double-blind , parallel-group , multicenter , trial 3 dos levalbuterol tartrate HFA inhalation aerosol MDI pediatric subject birth ≤ 48 month age present either Emergency Department ( ED ) physician 's office acute bronchospasm . Subjects present ED physician 's office acute bronchospasm must history reactive airway disease , base subject ' parent/guardian report . Eligible subject whose parent ( ) legal guardian ( ) provide write informed consent participate randomize 1 2 treatment . Treatment 1 consist 3 dos , dose comprise 8 puff ( 4 puff levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puff placebo HFA [ cumulative dose 540 mcg levalbuterol tartrate HFA inhalation aerosol ] ) ; Treatment 2 consist 3 dos , dose comprise 8 puff levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff ( 4 puff levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puff levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff [ cumulative dose 1080 mcg levalbuterol tartrate HFA inhalation aerosol ] ) . For Treatment , study medication administer every 20 minute period 1 hour three dos .</detailed_description>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Male female birth 48 month age , inclusive , whose parent ( ) legal guardian ( ) provide write informed consent prior study participation willing comply study procedure . 2 . Subject experience acute bronchospasm require bronchodilator history wheeze . 1 . Subject severe illness , opinion Investigator , could jeopardize subject safety . 2 . Subject receive ≥ 8 puff ( MDI ) beta2 agonist 2.5 mg nebulized levalbuterol , albuterol 5.0 mg within 4 hour prior ED physician 's office admittance . 3 . Subject receive ipratropium within 4 hour prior ED physician 's office admittance . 4 . Subject participate investigational drug study within 30 day prior enrollment , previously participate current study . 5 . Subject know sensitivity levalbuterol racemic albuterol excipients contain formulation . 6 . Subject use prescription drug ( include betablockers ) levalbuterol racemic albuterol sulfate administration contraindicate . 7 . Subject history clinically significant abnormality could interfere metabolism excretion study medication ( eg , renal , hepatic , metabolic , endocrine abnormality ) . 8 . Subject history cancer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute Asthma exacerbation</keyword>
</DOC>